Log in with your email address username.


[Articles] Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study

In children with chronic immune thrombocytopenia, romiplostim induced a high rate of platelet response with no new safety signals. Ongoing romiplostim studies will provide further information as to long-term efficacy, safety, and remission in children with immune thrombocytopenia.